Sign in

SCNX on Nasdaq

Scienture Holdings, Inc.

Scienture Holdings, Inc. is an American pharmaceutical preparations company based in Commack.1 Its shares trade on Nasdaq under the symbol SCNX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with XTL Bio, MEDICINOVA INC or Can Fite Biopharma, or pick any stock.

  • TickerSCNX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCommack, New York1
  • Incorporated inDE2
  • Business address20 Austin Blvd., Commack, Ny 117252
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

LLC became a wholly owned subsidiary of the Company. Scienture’s principal executive offices are located in Commack, New York.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

76.8%Gross margin4
-9867.9%Operating margin4
-9618.0%Net margin4
215.9%Revenue growth, 20254
-59.2%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue2¢$100.1K
  • Research and development48¢$2.0M
  • Income tax49¢$2.0M

Out of $431.6K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$431.6K in 2025−94% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $7.4M$7.4M20192020: $17.1M$17.1M2020+130%2021: $9.9M$9.9M2021−42%2022: $10.3M$10.3M2022+4%2023: $1.4M$1.4M2023−87%2024: $136.6K$136.6K2024−90%2025: $431.6K$431.6K2025+216%
Gross profit567894$331.5K in 2025−93% since 2019
0$2.0M$4.0M$6.0M2019: $4.9M$4.9M20192020: $5.7M$5.7M2020+17%2021: $4.7M$4.7M2021−17%2022: $5.5M$5.5M2022+16%2023: $49.0K$49.0K2023−99%2024: $6.0K$6.0K2024−88%2025: $331.5K$331.5K2025+5420%
Operating income567894-$42.6M in 2025
-$60.0M-$40.0M-$20.0M0$20.0M2019: $125.2K$125.2K20192020: -$2.5M-$2.5M20202021: -$5.3M-$5.3M2021+111%2022: -$2.9M-$2.9M2022−45%2023: -$4.4M-$4.4M2023+51%2024: -$14.7M-$14.7M2024+234%2025: -$42.6M-$42.6M2025+190%
Net income567894-$41.5M in 2025+14495% since 2019
-$60.0M-$40.0M-$20.0M0$20.0M2019: -$284.4K-$284.4K20192020: -$2.5M-$2.5M2020+792%2021: -$5.3M-$5.3M2021+110%2022: -$3.5M-$3.5M2022−35%2023: -$17.8M-$17.8M2023+414%2024: $9.1M$9.1M20242025: -$41.5M-$41.5M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues$431.6K$136.6K
Cost of sales$100.1K$130.6K
Gross profit$331.5K$6.0K
Wage and salary expense$2.1M$2.1M
Professional fees$2.4M$1.5M
Accounting and legal expense$2.1M$1.8M
Technology expense$97.3K$416.3K
General and administrative$7.9M$6.7M
Research and development$2.0M$2.2M
Impairment loss$26.3M
Total operating expenses$42.9M$14.7M
Operating loss-$42.6M-$14.7M
Change in fair value of warrant liability$909.0K-$183.0K
Change in fair value of derivative liability$2.3M$180.4K
Impairment of investment-$2.5M
Loss on conversion of note payable-$53.4K
Loss on disposition of subsidiaries-$288.2K
Interest income$302.7K$135.3K
Loss on disposal of asset-$375.0K
Interest expense-$4.1M-$1.3M
Total non-operating expense-$916.3K-$4.1M
Net loss from continuing operations-$43.5M-$18.8M
Benefit / (provision) for income taxes$2.0M$534.4K
Net loss from continuing operations, net of tax-$41.5M-$18.2M
Net income from discontinued operations, net of tax$27.3M
Net (loss) income-$41.5M$9.1M
Basic-$3-$5
Diluted-$3-$5
Basic$8
Diluted$7
Basic-$2.70$2.69
Diluted-$2.70$2.48
Basic15.3M shares3.4M shares
Diluted15.3M shares3.7M shares

Compare Scienture Holdings, Inc. with another company

Corporate structure

Scienture Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Scienture Holdings, Inc.

  • Scienture Holdings, Inc. Commack, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Scienture Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$15.5K4 Dec 31, 2025$17.5K4 Dec 31, 2024−11.4%
Operating-lease assets (leased space)$23.4K4 Dec 31, 2025$201.4K4 Dec 31, 2024−88.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.7M4 Dec 31, 2025$151.9K8 Dec 31, 2023+4285.6%
Deposits held (banks)$1.2M4 Dec 31, 2025

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$21.4M4 Dec 31, 2024$07 Dec 31, 2022
Intangible assets, net (excluding goodwill)$71.0M4 Dec 31, 2025$76.4M4 Dec 31, 2024−7.1%
Indefinite-lived intangibles (excluding goodwill)$71.0M4 Dec 31, 2025$76.4M4 Dec 31, 2024−7.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$213.4K4 Dec 31, 2025$9689 Dec 31, 2023+21946.3%
Finished goods$213.4K4 Dec 31, 2025$9689 Dec 31, 2023+21946.3%

Properties, in its own words

We do not own any real property.

Scienture LLC entered into a lease at 20 Austin Boulevard, Commack, NY 11725 for approximately $29,621 per year ($2,468 per month) under a 22-month agreement, effective October 1, 2023.

The rest of Item 2

We believe our current and future facilities are adequate for our current and near-term needs. Additional space may be required as we expand our activities. We do not currently foresee any significant difficulties in obtaining any required additional facilities.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led Scienture Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Surendra K. Ajjarapu2014–2024
  2. Hariharan Shankar2026–now

Chair

  1. Surendra K. Ajjarapu2014–2024
  2. Hariharan Shankar2026–now

Chief financial officer

  1. Howard A. Doss2014–2020
  2. Janet Huffman2022–2023
  3. Eric Michael Sherb2026–now
201520202025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorNarasimhan Mani named Dec 19, 2024 to Aug 7, 202528
  • Executive Officer, DirectorShankar Hariharan named Dec 19, 2024 to Aug 7, 202528
  • Executive Officer, DirectorPrashant Patel named Dec 19, 202429
  • DirectorMayur G. Doshi named Dec 19, 2024 to Aug 7, 202528
  • DirectorSubbarao G. Jayanthi named Dec 19, 2024 to Aug 7, 202528

Former names

  • TRxADE HEALTH, INCJun 2, 2021 to Aug 28, 20242
  • TRXADE GROUP, INC.Jun 11, 2014 to May 28, 20212
  • XCELLINK INTERNATIONAL INC.Nov 18, 2008 to Jan 31, 20142
  • Bluebird Exploration Co.Jun 15, 2007 to Dec 10, 20082

Timeline

  1. Oct 7, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure30
  2. Sep 14, 20268-K Regulation FD disclosure31
  3. Aug 20, 20268-K Results of operations32
  4. May 29, 20268-K Executive or director change33
  5. May 22, 20268-K Results of operations34
  6. May 5, 20268-K Regulation FD disclosure35
  7. May 1, 20268-K Entered a material agreement; New debt or obligation36
  8. Mar 12, 2026New chief executive Hariharan Shankar becomes CEO13
  9. Nov 18, 20258-K Regulation FD disclosure37
  10. Nov 14, 20258-K Shareholder vote38
  11. Nov 13, 20258-K Other events39
  12. Oct 30, 20258-K Other events40
  13. Oct 24, 20258-K Entered a material agreement41
  14. Aug 14, 2014New chief executive Surendra K. Ajjarapu becomes CEO14

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($4.75) a share, on Nov 12, 2025.42

When it reported results

  1. Aug 20, 2026Reported quarterly or annual results32
  2. May 22, 2026Reported quarterly or annual results34
  3. May 15, 2023Reported quarterly or annual results43
  4. Mar 27, 2023Reported quarterly or annual results44
  5. Nov 7, 2022Reported quarterly or annual results45
  6. Jul 26, 2022Reported quarterly or annual results46
  7. Jul 25, 2022Reported quarterly or annual results47
  8. May 9, 2022Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

244 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 96 major events, 26 insider forms, 7 large holders, 3 private raises, 89 other. The latest 20:

  1. Oct 7, 20268-K EDGAR
  2. Sep 18, 2026DEF 14A EDGAR
  3. Sep 14, 20268-K EDGAR
  4. Sep 8, 2026PRE 14A EDGAR
  5. Aug 31, 20265 EDGAR
  6. Aug 31, 20263 EDGAR
  7. Aug 20, 20268-K EDGAR
  8. Aug 13, 202610-Q EDGAR
  9. May 29, 20268-K EDGAR
  10. May 22, 20268-K EDGAR
  11. May 15, 202610-Q EDGAR
  12. May 5, 20268-K EDGAR
  13. May 1, 20268-K EDGAR
  14. Apr 30, 202610-K/A EDGAR
  15. Mar 30, 202610-K EDGAR
  16. Mar 12, 20264 EDGAR
  17. Mar 12, 20264 EDGAR
  18. Nov 18, 20258-K EDGAR
  19. Nov 14, 20258-K EDGAR
  20. Nov 14, 2025SCHEDULE 13G/A EDGAR

The 244 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 25, 2022Fell Donald G.DirectorBuy1,500$1.08$1.6KForm 4
May 20, 2022AJJARAPU SURENDRA KChairman and CEOBuy10,000$1.30$13.0KForm 4
May 20, 2022AJJARAPU SURENDRA KChairman and CEOBuy10,000$13,000.00$130.0MForm 4
May 12, 2022Fell Donald G.DirectorBuy2,000$1.26$2.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Dr. Narasimhan Mani52$333.2K$1.3M54
2025Dr. Shankar Hariharan69$233.2K$1.2M54
2025Eric Sherb$83.3K$128.3K54
2025Surendra Ajjarapu$100.0K54
2024Former Chairman of the BoardChief Executive Officer, and Secretary$484.2K$570.6K54
2024Former PresidentChief Operating Officer, and Interim Principal Financial/ Accounting Officer$333.0K$409.5K54
2024Former Chief Financial Officer$82.5K54

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 18, 2025Raised $1.7 million in a private offering of equity Form D: $3 million offered in all Form D
  2. Nov 25, 2024Raised $3.3 million in a private offering of securities Form D: 2 investors so far Form D

SEC filer profile

How Scienture Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARScienture Holdings, Inc.1
  • CIK0001382574
  • Employer ID (EIN)46-36739283
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address20 Austin Blvd., Commack, NY 117251
  • Phone(800) 261 02811
  • Shares outstanding41,064,146 as of Aug 13, 202611
  • Public float$10.2M as of Jun 30, 20253
  • AuditorCM3 Advisory, San Diego, California PCAOB ID 6866; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJun 15, 20071
  • Filings505 in all: 8-K (156), 4 (50), 10-Q (43), CORRESP (24), UPLOAD (22), 3 (16), 10-K (13), D (12)1
    All 54 form types

    EFFECT (12), 424B3 (9), S-1/A (9), 424B5 (8), 8-K/A (8), DEF 14A (8), DEF 14C (8), NT 10-Q (8), PRE 14C (8), S-1 (7), PRE 14A (6), 10-K/A (5), 10-Q/A (5), 4/A (5), DEFA14A (5), SC 13D/A (5), 5 (4), DEFR14C (4), S-3 (4), 10-12G/A (3), DRS (3), NT 10-K (3), SC 13D (3), 10QSB (2), 425 (2), PRER14A (2), SC 13G (2), SC 13G/A (2), SCHEDULE 13G (2), 1-A (1), 1-A-W (1), 1-A/A (1), 10-12G (1), 10KSB (1), 10KSB/A (1), 15-15D (1), 424A (1), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), POS AM (1), S-8 (1), SB-2 (1), SCHEDULE 13G/A (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Sep 18, 2026
    Latest 8-K (8-K) Oct 7, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.00001 Par Value Per ShareSCNXNASDAQ

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Scienture Holdings, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 47 risks under these headings, as written.3

  • You should be aware that there are substantial risks for an investment in our common stock. You should carefully consider these risk factors before you decide to invest in our common stock and should not consider this list to be a complete statement of all risks and uncertainties.
  • If any of the following risks were to occur, such as our business, financial condition, results of operations or other prospects, any of these could materially affect our likelihood of success. If that happens, the market price of our common stock, if any, could decline, and prospective investors would lose all or part of their investment in our common stock.
  • Risks Related to Our Business
  • We operate a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate its current business and predict its future success and viability.
  • We need additional capital which may not be available when needed or on commercially acceptable terms. Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.
  • Due to the significant resources required to develop our product pipeline, and depending on our ability to access capital, we must prioritize the development of certain product candidates over others and we may fail to expend our limited resources on product candidates or indications that may have been more profitable or for which there is a greater likelihood of success.
  • Our acquisitions and investments in new businesses and new products, services, and technologies is inherently risky, and could disrupt our ongoing businesses.
  • Our business is highly dependent on the success of certain product candidates. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed.
  • We are dependent upon our current management, who may have conflicts of interest. Our ability to develop product candidates and our future growth depends on attracting, hiring and retaining key personnel and recruiting additional qualified personnel.
  • We may seek to collaborate with third parties and may not be able to implement these collaborations on commercially acceptable terms, if at all. The success of certain of our product candidates may depend in significant part on the success of such collaborations.
  • Our third-party manufacturing partners may be unable to increase the scale of production or product yield of our product candidates, resulting in increased manufacturing costs and delays in commercialization of our products. Furthermore, changes in methods of manufacturing our product candidates could result in additional costs or delays.
  • Our growth depends in part on the success of our strategic relationships with third parties. Some of these third parties may be located outside of the United States.
The other 36 risks
  • Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
  • We may be subject to lawsuits.
  • The successful development of our pharmaceutical products involves a lengthy and expensive process and is highly uncertain.
  • Risks Related to Our Legal and Regulatory Requirements
  • We are subject, directly or indirectly, to federal and state healthcare, fraud, abuse false claims, and other laws and regulations as well as health data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply, or have not fully complied, with such laws, we could face investigations and substantial penalties. Furthermore, it may be difficult and costly for us to comply with the extensive government regulations to which our business is subject.
  • We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our business and results of operations.
  • Even if we obtain regulatory approval for any of our product candidates, we will be subject to ongoing regulatory requirements, which may result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • We intend to use certain regulatory pathways to seek regulatory approval of several of our product candidates. If the FDA concludes that our marketing applications no longer qualify for these regulatory pathways, then our applications may not be accepted by the FDA for review and approval of our products may be delayed.
  • We may seek priority review designation for our product candidates. We might not receive such designation, and even if we do, such designation may not lead to faster regulatory review or approval.
  • We may seek orphan drug designation from the FDA for our product candidates. We may be unable to obtain such designation or, if obtained, to maintain the benefits associated with orphan drug status, including the potential for non-patent market exclusivity.
  • If regulatory authorities approve generic versions of our products, or do not grant our products a sufficient period of market exclusivity before approving a generic version, our ability to generate revenue may be adversely affected.
  • Even if we obtain FDA approval for a product candidate in the United States, we may never obtain approval for or successfully commercialize that candidate outside of the United States, which would limit our ability to realize a product’s full market potential.
  • Even if we are able to commercialize any of our product candidates, the third-party payor coverage and reimbursement status of newly-approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue.
  • We are developing a drug-device combination product, which may result in additional regulatory risks.
  • Our third party collaborators and service providers are, or may become, subject to a variety of stringent and evolving privacy and data security laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy and data security. Any actual or perceived failure to comply with such obligations could expose us to significant fines or other penalties and otherwise harm our business and operations.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • Healthcare legislative reform measures may have a negative impact on our business and results of operations.
  • Inadequate funding for the FDA and other government agencies, including from government shutdowns, or other disruptions to these agencies’ operations, could hinder such agencies’ ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely.
  • Risks Related to Our Technology and Intellectual Property
  • We may not be able to protect our intellectual property and trade secret rights throughout the world. If our efforts to protect our intellectual property rights are inadequate, we may not be able to compete effectively in our market.
  • We depend on in-licensed intellectual property. If we fail to comply with our obligations under intellectual property licenses with third parties, we could lose license rights that are important to our business.
  • If we or our licensors are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our product candidates, and our ability to successfully commercialize our product candidates may be adversely affected. Furthermore, we do not intend to seek patent protection for one of our products, SCN-106.
  • Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.
  • Changes to patent law in the United States and in foreign jurisdictions could diminish the value of our patents in general, thereby impairing our ability to protect our product candidates.
  • If we do not obtain patent term extension for our current product candidates, our business may be materially harmed.
  • We may become involved in lawsuits to protect or enforce our intellectual property rights, which could be distracting, expensive, time consuming, and unsuccessful.
  • We may be subject to claims challenging the inventorship or ownership of our intellectual property or asserting that we violated intellectual property rights of others, the outcome of which would be uncertain. These claims could be extremely costly to defend, could require us to pay significant damages and limit our ability to operate, and could distract our personnel from normal responsibilities.
  • European patents and patent applications could be challenged in the recently created Unified Patent Court for the European Union.
  • Our use, or the use by our third party collaborators and service providers, of new and evolving technologies, such as artificial intelligence (“AI”) and machine learning (“ML”), may result in spending additional resources and present new risks and challenges that can impact our business, including by posing security and other risks to our sensitive data. As a result, we may be exposed to reputational harm, other adverse consequences, and liability.
  • If our trademarks and trade names are not adequately protected then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Risks Related to Our Common Stock
  • We may not be able to comply with Nasdaq’s continued listing standards.
  • Our common stock has in the past been a “penny stock” under SEC rules, and may be subject to the “penny stock” rules in the future. It may be more difficult to resell securities classified as “penny stock.”
  • The exercise of outstanding warrants, options and other securities that are exercisable into shares of our common stock will be dilutive to our existing stockholders.
  • We have not historically paid or declared any dividends on our common stock and do not expect to pay or declare cash dividends in the future on a regular basis, if at all.
  • Our common stock price is likely to be highly volatile because of several factors, including a limited public float.
  • There may not be sufficient liquidity in the market for our securities in order for investors to sell their shares. The market price of our common stock may continue to be volatile.
  • Stockholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares of our common stock.

Legal proceedings

In the ordinary course of business, we may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We believe the ultimate resolution of any such current proceeding will not have a material adverse effect on our continued financial position, results of operations or cash flows, except as otherwise set forth below. However, assessment of the current litigation or other legal claims could change in light of the discovery of facts not presently known to the Company or by judges, juries or other finders of fact, which are not in accord with management’s evaluation of the possible liability or outcome of such litigation or claims.

For a description of our material pending legal proceedings, please see “Note 13 – Commitments and Contingencies” to the Notes to Consolidated Financial Statements included herein under “Item 8. Financial Statements and Supplemental Data.”

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54